PUBLIC COMPANY
save$BDTXBlack Diamond Therapeutics, Inc.
$BDTXCambridge, MA, USupdated 21d ago
community read0 votes
pipeline
1
marketed
0
phase 3
0
catalysts ytd
0
approvals ytd
0
recalls ytd
0
Pipeline(1)
pipeline depth1 products
1Phase 2
Upcoming
no upcoming catalysts on record
Recent(90d)
nothing in the last 90 days
view all catalysts →Active trials
- phase2Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIII
- phase2Phase 1/2 Study of Silevertinib (BDTX-1535) in Patients With Glioblastoma or Non-Small Cell Lung Cancer With EGFR Mutations
- phase1A Study of BDTX-189, an Orally Available Allosteric ErbB Inhibitor, in Patients With Advanced Solid Tumors.
Insider activity
source: SEC Form 4routine RSU / option mechanics (2)
- Mar 20, 26grantBehbahani Ali · director6,919 sh
- Mar 20, 26grantRaman Prakash · 6,105 sh
🐶 Hiring Signal
News
no news has mentioned this company yet
Data sources
last refreshed 11m ago
Found something off?
comments(0)
5-min edit window · permanent after that